Fast-acting modified botulinum neurotoxin
By engineering mutations in the belt-buckle region of BoNT/A to enhance flexibility, the modified toxin achieves faster onset and maintains potency, addressing the limitations of existing BoNTs in medical and cosmetic applications.
Patent Information
- Application Number
- PCT/US2026/027093
- Authority / Receiving Office
- WO · WO
- Patent Type
- Applications
- Current Assignee / Owner
- Priority Date
- 2025-05-09
- Filing Date
- 2026-05-07
- Publication Date
- 2026-11-12
AI Technical Summary
Current botulinum neurotoxins (BoNTs) either have slow onset or low potency, limiting their effectiveness in medical and cosmetic applications, with the molecular mechanisms for varying onset speeds unclear.
Engineer mutations in the belt-buckle region of BoNT/A to increase its flexibility, allowing faster onset of action while maintaining potency and duration, by destabilizing the belt-buckle using mutations like W460G, F464G, and Y543G, or stabilizing it with antibodies.
The modified BoNT/A exhibits a faster onset of action and comparable potency and duration, suitable for neurologic conditions requiring swift intervention and cosmetic treatments seeking rapid results.
Smart Images

Figure US2026027093_12112026_PF_FP_ABST
Abstract
Description
Reference No.: UC2024-9AO, UCI 25.03 PCTInventor’s last name: Jin et alDocument Date: May 7, 2026FAST-ACTING MODIFIED BOTULINUM NEUROTOXINCROSS-REFERENCE TO RELATED APPLICATIONS
[0001] This application claims benefit of U.S. Provisional Application No. 63 / 803,151 filed May 9, 2025, the specification of which is incorporated herein in its entirety by reference.STATEMENT REGARDING FEDERALLY SPONSORED RESEARCH OR DEVELOPMENT
[0002] This invention was made with government support under Grant No AI173059 and AI125704 awarded by the National Institutes of Health The government has certain rights in the invention REFERENCE TO AN ELECTRONIC SEQUENCE LISTING
[0003] The contents of the electronic sequence listing (UCI_25_03_PCTxml; Size: 21,032 bytes; and Date of Creation: May 7, 2026) is herein incorporated by reference in its entirety.FIELD OF THE INVENTION
[0004] The present invention relates to botulinum neurotoxin (BoNT), including medical and cosmetic applicationsBACKGROUND OF THE INVENTION
[0005] Members of the botulinum neurotoxin family have been developed into powerful medicines and popular cosmetics. BoNT / E takes effect faster than that of BoNT / A and BoNT / B. However, the molecular mechanisms that determine the different speed of onset among different BoNTs remains largely unknown
[0006] BoNTs have seven major serotypes (termed BoNT / A-G). However, BoNT / A and BoNT / B are the only two to have received FDA approval for medical and cosmetic applications, following research spanning over half a century. Currently, almost all commercial BoNT products worldwide are based on BoNT / A (e.g. Botox®, Dysport®, Xeomin®, Jeuveau®, Daxxify® et al), which exhibits a high potency and a long duration. In comparison, there is only one BoNT / B product available (Myobloc / Neurobloc®), which suffers from low potency in humans. Interestingly, BoNT / E takes effect usually within 1-day post-injection, which is much faster than that of BoNT / A (-7 days) and BoNT / B However, BoNT / E exhibits lower potency and shorter duration of action compared to BoNT / A. Therefore, there are strong needs to develop novel fast-acting BoNTs with high potency and long duration. The molecular mechanisms that dictate the different speed of onset among different BoNTs remains largely unknown.
[0007] At the molecular level, each BoNT molecule is composed of a ~50 kDa light chain (LC) and a -100 kDa heavy chain (HO), where the HO consists of an N-terminal translocation domain (HN) and a C-terminal receptor-binding domain (Hc). BoNTs specifically target cholinergic neurons through their Hcdomains that synergistically bind complex gangliosides and specific protein receptors on the neuron surface. Upon entering neurons by receptor-mediated endocytosis and triggered by vesicle acidification, the LC partially unfolds and translocates across the endosomal membrane facilitated by the HNThe LC then refolds in the cytosol and specifically cleaves SNARE (soluble N-ethylmaleimide-sensitive factor attachment protein receptor) complexes. This blocks vesicle fusion and prevents the release of acetylcholine, resulting in paralysis of the affected muscles. Both BoNT / A and BoNT / E exploit synapticReference No.: UC2024-9AO, UCI 25.03 PCTInventor’s last name: Jin et alDocument Date: May 7, 2026vesicle glycoprotein 2 (SV2) as the receptor and cleave the same substrate SNAP-25 with similar activity, suggesting that receptor binding and LC activity are unlikely the major determinants for the significantly different speed of onset for BoNT / A and BoNT / E.BRIEF SUMMARY OF THE INVENTION
[0008] It is an objective of the present invention to provide compositions and methods that allow for modified botulinum neurotoxins with an improved onset of action, while maintaining potency and duration of effect, as specified in the independent claims Embodiments of the invention are given in the dependent claims. Embodiments of the present invention can be freely combined with each other if they are not mutually exclusive
[0009] The present invention focuses around the “belt” of BoNTs, a largely unstructured loop wrapping around their catalytic light chain (LC), which has been discovered to act as a rate-limiting factor during intoxication. High flexibility of the belt on BoNT / E helps to lower the energy requirement for acidic pH-induced LC unfolding and LC delivery into the neuronal cytosol, leading to fast onset of action. A regulatory checkpoint within the belt was identified (termed belt-buckle), which may modulate the loosening of the belt’s constraint on the LC in response to vesicle acidification. Destabilizing the belt-buckle of BoNT / A by protein engineering facilitates the pH-dependent conformational change of BoNT / A, resulting in a fast onset of action. In contrast, locking the belt-buckle of BoNT / A via an antibody prevents belt release, thereby neutralizing the toxin. The present invention features a novel mechanism by which BoNTs regulate their speed of onset, opening new avenues to develop fast acting BoNTs to treat neurologic conditions needing swift intervention and timely evaluation of treatment outcomes, as well as for cosmetic customers seeking rapid results, and, conversely, effective countermeasures.
[0010] BoNT / A and BoNT / B display a linear “open-wing”-like arrangement where the Hcand LC are located on opposite sides of the long helical HN, while the Hcand the LC-HNof BoNT / E fold toward each other resulting in a “closed-wing” conformation. The prevailing view was that the closed-wing conformation of BoNT / E may be more efficient for LC translocation, and the open form of BoNT / A and B may need to switch into the BoNT / E-like closed conformation prior to acidic-pH triggered LC translocation. However, this hypothesis is largely based on structures of BoNT / A, B, and E determined around neutral pH, with their responses to endosome acidification remaining unknown. However, in contravention to this traditional way of thinking, it was instead surprisingly found that BoNT / E adopts an ensemble of open conformations at acidic pH, a signal inside the neurons for LC unfolding and translocation, including a BoNT / A-like open-wing conformation. This surprising finding marks a paradigm shift, which led to focus on other unique features of BoNT / E, eventually identifying the belt-buckle, which could be engineered to modulate the speed of BoNT action. Furthermore, while all the known prior art teaches that the belt is a surrogate pseudo-substrate inhibitor of the LC protease, it was surprisingly found that the belt is involved in regulating the speed of the onset of BoNT action.
[0011] To better understand the molecular mechanisms underlying BoNT / E’s quick action, the structure of BoNT / E was examined at acidic pH using cryogenic electron microscopy (cryo-EM). Surprisingly, it wasReference No.: UC2024-9AO, UCI 25.03 PCTInventor’s last name: Jin et alDocument Date: May 7, 2026found that BoNT / E adopts a series of dynamic open conformations at acidic pH with Hcmoving away from the LC-HNdomain. Notably, it was found that the N-terminal region of the HC of BoNT / E (residues K423-N515), which is largely unstructured and wraps around the LC via extensive interactions (hence referred to as the “belt” segment), exhibits greater flexibility compared to the belts of BoNT / A and BoNT / B. The belt may be a surrogate pseudo-substrate inhibitor of the LC protease Without wishing to limit the present invention to any particular theory or mechanism, compared to BoNT / A, the looser belt of BoNT / E may exert weaker constraint on LC / E, enabling it to unfold more rapidly, leading to quicker translocation and earlier action of the LC / E in the cytosol, ultimately resulting in a faster onset. Conversely, in some embodiments, the present invention may feature a more rigid belt of BoNT, thereby slowing the onset of action or disabling the toxin partially or entirely. In some embodiments, the belt of BoNT may be made more rigid by an antibody binding to the BoNT toxin.
[0012] “Reverse engineering” of BoNT / A was performed to loosen its belt by structure-based mutagenesis. These experiments led to the identification of a unique area on the belt where its C-terminal end, after wrapping around the LC like a strap, circles back in 3-dimension to reunite with its N-terminal end, forming a buckle-like motif (termed belt-buckle) Destabilizing this area, such as by using various combinations of one or more of W460G, F464G, and Y543G mutations, decreased the structural stability of the LC-HNfragment of BoNT / A and sped up its acidic pH-triggered conformational changes. Furthermore, an engineered BoNT / A holotoxin, with a loosened belt due to the W460G / F464G / Y543G mutations (BoNT / A-WFY), exhibited lower EC50 values at given time points compared to the wild-type (WT) BoNT / A in a neuron-based activity assay, indicating a quicker onset, while showing a modest reduction in activity in the mouse phrenic nerve hemidiaphragm (MPN) assay. An engineered BoNT / A-F variant (F464G) exhibited an improved potency (-206%) compared to WT BoNT / A based on the MPN assay. In some embodiments, a potent human neutralizing antibody against BoNT / A (2G11) neutralizes BoNT / A by stabilizing the belt-buckle area. Taken together, these studies demonstrated that the belt-buckle of BoNT serves as a critical speed-limiting checkpoint during its action, opening new avenues for developing fast-acting BoNTs while also laying the groundwork for further exploration of BoNT pathogenesis and potential countermeasures.
[0013] While the present invention is not limited to these mutations, in summary, various combinations of three mutations located in the belt, W460G, F464G, and Y543G (WFY), increases the flexibility of the belt and subsequently speeds up the acidic pH-dependent unfolding of the LC-HNfragment of BoNT / A. The LC-HNfragment of BoNT / A carrying these three mutations is more sensitive to acidic pH and unfolds faster and extensively than the WT protein. Without wishing to limit the present invention to any particular theory or mechanism, this should lead to an accelerated speed of onset in the context of BoNT / A holotoxin.
[0014] An engineered BoNT / A carrying mutations located in the belt involving W460G, F464G, and / or Y543G, exhibits a faster onset of action while maintaining other properties (e.g., potency and duration) comparable to the wild-type BoNT / A. A fast-acting BoNT / A, of the present invention will be more desirable for treating neurologic conditions requiring prompt therapy, as well as for cosmetic customers seekingReference No.: UC2024-9AO, UCI 25.03 PCTInventor’s last name: Jin et alDocument Date: May 7, 2026rapid results.
[0015] One of the unique and inventive technical features of the present invention is engineered mutations to the “belt-buckle” region of botulinum neurotoxin(s) that create a modified botulinum neurotoxin with a faster onset of action, while retaining receptor binding, LC activity, or most other intrinsic features of wild type botulinum neurotoxins. Without wishing to limit the invention to any theory or mechanism, it is believed that the technical feature of the present invention advantageously provides for “loosened” interactions between the belt and the LC, which lowers the energy requirement for the LC and HNto undergo partial unfolding and conformational change in response to endosomal acidic pH, and thereby lowering barriers to LC translocation and ultimately creating a modified protein with a faster onset of action, while maintaining properties such as potency and duration of effect at levels similar or identical to those in the wild type protein. None of the presently known prior references or works have the unique inventive technical feature of the present invention.
[0016] Moreover, the prior references teach away from the present invention. For example, all the known prior art teaches that the closed-wing conformation of BoNT / E is the main reason for its faster onset, compared to the open-wing conformation of BoNT / A and BoNT / B. Therefore, the conventional ideas to speed up the action of BoNT / A focused on howto engineer BoNT / A to mimic the closed-wing BoNT / E-like conformation. However, in contravention to this traditional way of thinking, it was instead surprisingly found that BoNT / E adopts an ensemble of open conformations at acidic pH, a signal inside the neurons for LC unfolding and translocation, including a BoNT / A-like open-wing conformation. This surprising finding marks a paradigm shift, which led to focus on other unique features of BoNT / E, eventually identifying the belt-buckle, which could be engineered to modulate the speed of BoNT action. Furthermore, while all the known prior art teaches that the belt is a surrogate pseudo-substrate inhibitor of the LC protease, it was surprisingly found that the belt is involved in regulating the speed of the onset of BoNT action.
[0017] Furthermore, the inventive technical features of the present invention contributed to a surprising result. For example, destabilizing the belt via introducing mutations on the belt to weaken its association with the LC is not necessarily sufficient to facilitate LC unfolding and translocation, suggesting the regulatory effect of the belt is not uniformly distributed across it. It was found that only mutations introduced within the critical belt-buckle area could effectively change the sensitivity to acidic pH, leading to more rapid and extensive unfolding.
[0018] Any feature or combination of features described herein are included within the scope of the present invention provided that the features included in any such combination are not mutually inconsistent as will be apparent from the context, this specification, and the knowledge of one of ordinary skill in the art. Additional advantages and aspects of the present invention are apparent in the following detailed description and claimsBRIEF DESCRIPTION OF THE SEVERAL VIEWS OF THE DRAWING(S)Reference No.: UC2024-9AO, UCI 25.03 PCTInventor’s last name: Jin et alDocument Date: May 7, 2026
[0019] The features and advantages of the present invention will become apparent from a consideration of the following detailed description presented in connection with the accompanying drawings in which:
[0020] FIGs. 1A-1D shows a structural comparison of the belts of BoNT / E and BoNT / A in the context of holotoxins. FIG. 1A shows a schematic representation of the domain organizations of BoNT / E and BoNT / A. FIG. 1B shows the crystal structure of BoNT / E (Protein Data Bank (PDB): 3FFZ) shown in surface representation. The belt is highlighted in red in the original drawing. FIG. 1C shows the crystal structure of BoNT / A (PDB: 3BTA) in surface representation, with its belt highlighted in magenta in the original drawing. The belt-buckle areas, where the N- and C-termini of the belt associate with the C-terminal tail of the LC, are highlighted in dashed boxes. FIG. 1D shows the crystal structure of BoNT / E (PDB: 3FFZ) shown in cartoon representation, as well as close-up views of the interface between BoNT / E belt and HCE, with, in the original drawing, the belt shown in red, HCE in lime green, and LC / E in pale cyan. Selected interacting residues are shown as sticks with hydrogen bond and salt bridge interactions shown as dashed lines.
[0021] FIGs. 2A-2F shows BoNT / E adopts various open conformations with a flexible belt at acidic pH. FIG. 2A and FIG. 2B show Cryo-EM structure of BoNT / Ei in the M-PTC conformation (Class 1) at pH 5. In the original drawing, LC / E is shown in light gray, the belt in red, HNE in light blue, and HCE in lime green. FIG. 2C shows cryo-EM maps of BoNT / Ei in four different minor classes at pH 5, revealing multiple open conformational states. The BoNT / A-like semi-closed and open conformations are outlined in a red (in the original drawing) or black dashed box, respectively. In the original drawing, the color scheme follows that of FIG. 2A. FIGs. 2D, 2E, and 2F show structural comparisons of the belts among BoNT / E open conformation, BoNT / E closed conformation, and BoNT / A, respectively. The dashed lines indicate areas with unresolved structures. FIG. 2E in particular shows HCE in the closed conformation of BoNT / E (highlighted with a green (in the original drawing) oval), which helps hold the belt.
[0022] FIGs. 3A-3B show mapping key residues on the belt of BoNT / A that regulate its constraints on LC / A. FIG. 3A and FIG. 3B show the crystal structure of BoNT / A (PDB: 3BTA) in cartoon representation. In the original drawing, LC / A is colored wheat, HNA in light blue, HCA in pale green, and the belt in magenta. The selected residues on the belt that were subjected for mutagenesis studies are shown as sticks and surfaces. FIG. 3A shows in part, in a dashed box, a close-up view of the belt-buckle area that is strategically located in between LC and HN. FIG. 3B shows a close-up view of the belt, highlighting the residues for mutagenesis studies
[0023] FIGs. 4A-4C show biochemical characterization of variants of LC-HN / A carrying mutations on the belt FIG. 4A shows the profiles of gel filtration chromatography of four LC-HN / A mutants compared to the WT protein. FIG. 4B shows pH-dependent unfolding of LC-HN / A variants probed by ANS dye. The values of fluorescence intensity at 482 nm were normalized to that of WT LC-HN / A at pH 8.4. The data are presented as mean ± SD; n = 3. FIG. 4C shows thermal stability of LC-HN / A variants at indicated pH. The data are presented as mean ± SD; n = 3.
[0024] FIGs. 5A-5B show characterization of the LC-HN / A variants. W: W460G mutation; F: F464GReference No.: UC2024-9AO, UCI 25.03 PCTInventor’s last name: Jin et alDocument Date: May 7, 2026mutation; Y: Y543G mutation; WT: wild-type LC-HN / A. FIG. 5A shows thermal stability of LC-HN / A variants at indicated pH. FIG. 5B shows pH-dependent unfolding of LC-HN / A variants probed by ANS dye. The values of fluorescence intensity at 482 nm were normalized to that of WT LC-HN / A at pH 7.4. The data are presented as mean ± SD; n = 3.
[0025] FIGs. 6A-6D show functional characterizations of the engineered BoNT / A-WFY. FIG. 6A shows that the WT BoNT / A and BoNT / A-WFY are monodispersed in solution based on SEC analysis. Mouse P19 neurons (P19N) were treated with WT BoNT / A or BoNT / A-WFY at indicated concentrations, washed after 2 hours, and subsequently subjected to Western blot analyses using a monoclonal anti-SNAP-25 antibody at 4, 8, 12 and 24 hours post BoNT addition. FIG. 6B shows representative immunoblots FIG.6C shows the percentage of SNAP-25 cleavage by the WT BoNT / A or BoNT / A-WFY, which was quantified using Imaged and analyzed by GraphPad Prism 10 software. Error bars represent standard deviation from three independent experiments. FIG. 6D shows the comparison of the activity of 3 pM of BoNT / A-WFY and 30 pM of WT BoNT / A at 4-24 hours.
[0026] FIG 7 shows that dosages of WT BoNT / A (3.3 pM) and BoNT / A-WFY (75 pM) causing similar paralytic half-times were pre-incubated with 3.5 mU / mL of BAT® or without antitoxin for 60 min at 37°C and then tested in the MPN-BNA assay to quantify neutralization by this equine polyclonal botulism antitoxin.
[0027] FIGs. 8A-8F show neutralizing antibody 2G11 recognizes the belt-buckle area on BoNT / A. FIG.8A shows the binding of 2G11 to BoNT / A variants as examined by a pull-down assay, left panel: LC-HN / A variants; Right panel: full-length BoNT / Ai and BoNT / Ai-WFY. Representative images from one of three independent experiments are shown. FIG 8B shows a cryo-EM map of the BoNT / Ai-2G11 complex in two different views. BoNT / Ai and the Fab fragment of 2G11 are, in the original drawing, colored dark blue and hot pink, respectively. FIG. 8C and FIG. 8D show cartoon representation of the structure of the BoNT / Ai-2G11 complex. BoNT / Ai and the Fab fragment of 2G11 are, in the original drawing, colored dark blue and hot pink, respectively, and the belt is highlighted in yellow in the original drawing. FIG. 8E shows close-up views into the BoNT / Ai-2G11 interface involving the belt. The key interacting residues are shown as sticks, while the rest of BoNT / Ai is displayed as a surface. FIG. 8F shows a close-up view into the BoNT / Ai-2G11 interface involving loop T247-Y250 in LC / A.
[0028] FIGs. 9A-9E shows structural comparison of the belts between BoNT / E and BoNT / A under various conditions. FIG. 9A-9C shows 2Fo-Fc electron density maps (contour level = 1.2, blue mesh in the original drawing) of the belts in the crystal structures of BoNT / E and BoNT / A. FIG. 9A shows the same in the “closed” conformation of BoNT / E (PDB: 3FFZ). FIG 9B shows the crystal structure of LC-HN / E (PDB: 7K84). FIG. 9C shows the crystal structure of BoNT / A holotoxin in the “open” conformation (PDB: 3BTA). FIG. 9D and FIG. 9E show the EM densities of the belt (contour level = 4.0, blue mesh in the original drawing) in the cryo-EM structures of LC-HN / E and BoNT / Ei holotoxin at pH 5.
[0029] FIG 10 shows an example of a cryo-EM data processing workflow of BoNT / Ei at pH 5. Examples of a cryo-EM micrograph and 2D classes were shown in the left panels.Reference No.: UC2024-9AO, UCI 25.03 PCTInventor’s last name: Jin et alDocument Date: May 7, 2026
[0030] FIGs. 11 A-11C show the cryo-EM structure of BoNT / Ei at pH 5. FIG. 11A shows the cryo-EM map of LC-HN / E at 3 A resolution FIG. 11 B shows a cartoon representation of the atomic model of LC-HN / E at pH 5. FIG. 11C shows structural superimposition of BoNT / Ei in class 1 conformation at pH 5 (cyan in the original drawing) with BoNT / E in the M-PTC form (purple in the original drawing) (PDB: 9ARJ) NTNH / E in the M-PTC is colored in gray in the original drawing
[0031] FIGs. 12A-12D shows functional characterization of the engineered BoNT / A-WFY. FIG. 12A shows the examination of the thrombin cleaved WT LC-HN / A and the WFY mutant by SDS-PAGE under reducing and non-reducing conditions. Thrombin cleavage was carried out at a 1:200 (thrombin: protein, w / w) ratio at room temperature for 2 hours. In FIG. 12B, the activated BoNT / A WT and WFY resolved on a reducing SDS-PAGE, each containing a short peptide including a thrombin cleavage site inserted between K438and A449in the LC-HC linker. The appearance of two LC bands observed for BoNT / A-WFY may result from additional cleavage at the natural cleavage site K438or another Arg / Lys upstream of the thrombin site in the linker, likely due to the increased flexibility in the belt. FIG. 12C shows the biological activity of BoNT / A WT and WFY that was examined using the mouse phrenic nerve hemidiaphragm (MPN) assay. FIG. 12D shows the mouse P19 neuron (P19N) assay. Neurons were treated with WT BoNT / A or BoNT / A-WFY at indicated concentrations, washed after 2 h, and subsequently subjected to Western blot analyses using a monoclonal anti-SNAP-25 antibody at 4, 8, 12 and 24 h post BoNT addition. “M” indicates the MW marker. Synaptobrevin2 was used as a control. Representative immunoblots from three independent experiments are shown.
[0032] FIG 13A-13B shows negative-stain EM analysis of BoNT / Ai-WT and BoNT / Ai-WFY. FIG. 13A shows the structure of wild-type BoNT / A (PDB: 3BTA) highlighting the three major domains: light chain (LC, red in the original drawing), translocation domain (HN, green in the original drawing), and receptor-binding domain (Hc, magenta in the original drawing). Representative 2D template views generated by CryoSPARC are shown on the right, with arrows indicating the approximate positions of each domain. FIG. 13B shows the representative 2D class averages of BoNT / Ai-WT and BoNT / Ai-WFY obtained from negative-stain EM. Selected class averages are shown, with arrows marking the approximate positions of LC, HN, and Hc.
[0033] FIG 14 shows the workflow of cryo-EM analysis of BoNT / Ai-WFY. Examples of a cryo-EM micrograph and 2D classes were shown in the right panels. The crystal structure of wild-type BoNT / A (PDB: 3BTA) is fitted into the BoNT / Ai-WFY density map to illustrate the overall domain arrangement.
[0034] FIG 15 shows an example workflow of cryo-EM reconstruction of the BoNT / AI-2G11 complex. On the left, the quality of the BoNT / Ai-2G11 complex used for cryo-EM studies was characterized by SEC and SDS-PAGE. In the center, an example workflow of cryo-EM data processing and structure determination of the BoNT / Ai-2G11 complex is shown. On the right, examples of a cryo-EM micrograph and 2D classes are shown.
[0035] FIG 16A-16D show structural comparisons among the 2G11-bound BoNT / Ai, the free BoNT / A, and the isolated LC / A. FIG. 16A shows structural superposition of the 2G11-bound BoNT / Ai (BoNT / Ai:Reference No.: UC2024-9AO, UCI 25.03 PCTInventor’s last name: Jin et alDocument Date: May 7, 2026dark blue in the original drawing; 2G11: hot pink in the original drawing; belt: yellow in the original drawing), apo BoNT / A (wheat in the original drawing, PDB: 3BTA), and LC-HN / A (grey in the original drawing, PDB: 2W2D) FIG. 16B-16D show the structural superposition of the 2G11-bound BoNT / Ai (dark blue in the original drawing) with three representative structures of the isolated LC / A (colored in wheat in the original drawing) FIG 16B shows the structural superposition of the 2G11-bound BoNT / Ai (dark blue in the original drawing) with PDBs 2IMC. The loop in the LC that is engaged in 2G11 binding is missing. FIG. 16C shows the structural superposition of the 2G11-bound BoNT / Ai (dark blue in the original drawing) with 1E1H. The loop in the LC that is engaged in 2G11 binding is partially missing while the visible part exhibits a large conformational change. FIG. 16D shows the structural superposition of the 2G11-bound BoNT / Ai (dark blue in the original drawing) with 1XTF. The loop in the LC that is engaged in 2G11 binding is exhibiting a large conformational change.
[0036] FIG 17 shows antibodies 2G11 and JLE-E9 specifically recognize the belt-buckle in BoNT / A and BoNT / E, respectively, in a similar manner. The structures of the BoNT / Ai-2G11 (BoNT / Ai: light blue in the original drawing, VHof 2G11: hot pink in the original drawing, VLof 2G11: light pink in the original drawing) complex and the LC-HN / E-E9 (LC-HN / E: grey in the original drawing, E9: green in the original drawing) complex were superimposed based on their LC-HNfragments.
[0037] FIG 18A-18B show the belt is structurally conserved among BoNT / A, B, and E. FIG. 18A shows the structure of BoNT / A, which is shown as a gray transparent surface in the original drawing, while the belts of BoNT / A, B, and E are shown as cartoons that are, in the original drawing, colored blue, green, and brown, respectively FIG. 18B shows the amino acid sequence alignment among BoNT / A1 (Hall strain), BoNT / B1, and BoNT / E1 (Beluga strain) focusing on the belt segments. The belt-buckle area (A449-D474 and P532-D546 in BoNT / A1) is indicated by (in the original drawing, blue-colored) bars on the top. The sequence conservation is shown at the bottom: an asterisk (*) indicates fully conserved residues, a colon (:) signifies conservation between groups of strongly similar properties, and a period (.) indicates conservation between groups of weakly similar properties.
[0038] FIG 19A-19B show the amino acid sequence alignment of various BoNT / A and BoNT / B subtypes, focusing on the belt segment. The belt segments are highly conserved within all subtypes of BoNT / A and BoNT / B. Identical residues are indicated with white letters on a red (in the original drawing) background, similarly conserved residues are in red (in the original drawing) letters, and varied residues are in black letters. FIG. 19A shows the amino acid sequence alignment among eight BoNT / A subtypes (A1-A8) FIG. 19B shows the amino acid sequence alignment among eight BoNT / B subtypes (B1-B8).
[0039] FIGs. 20A-20B show biochemical characterization of the LC-HN / B variants carrying mutations on the belt. FIG. 20A shows pH-dependent unfolding of LC-HN / B variants probed by ANS dye. The values of fluorescence intensity at 482 nm were normalized to that of WT LC-HN / B at pH 8.4. FIG. 20B shows the thermal stability of LC-HN / B variants at the indicated pH levels. The data are presented as mean ± SD; n = 3.DETAILED DESCRIPTION OF THE INVENTIONReference No.: UC2024-9AO, UCI 25.03 PCTInventor’s last name: Jin et alDocument Date: May 7, 2026
[0040] Referring now to FIGs. 1A-20B, in some embodiments, the present invention features a modified botulinum toxin, the toxin comprising: one or more mutations to a belt-buckle region of the toxin; wherein the one or more mutations confer a faster onset of action as compared to a wild type botulinum toxin, while maintaining comparable potency and duration of action as the wild type botulinum toxin.
[0041] In some embodiments, the toxin is a botulinum toxin selected from one of botulinum toxin type A, botulinum toxin type B, botulinum toxin type C, botulinum toxin type D, botulinum toxin type F, or botulinum toxin type G
[0042] In some embodiments, the toxin is a botulinum toxin type A selected from botulinum toxin subtype Al, botulinum toxin subtype A2, botulinum toxin subtype A3, botulinum toxin subtype A4, botulinum toxin subtype A5, botulinum toxin subtype A6, botulinum toxin subtype A7, or botulinum toxin subtype A8
[0043] In some embodiments, the toxin is a botulinum toxin type B selected from botulinum toxin subtype B1, botulinum toxin subtype B2, botulinum toxin subtype B3, botulinum toxin subtype B4, botulinum toxin subtype B5, botulinum toxin subtype B6, botulinum toxin subtype B7, or botulinum toxin subtype B8.
[0044] In some embodiments, the toxin is a botulinum toxin type A, wherein the belt-buckle region comprises amino acids 449 to 474 and 532 to 546 of a BoNT / A1 toxin, BoNT / A2 toxin; a BoNT / A4 toxin, a BoNT / A5 toxin, a B0NT / A6 toxin, a BoNT / A7 toxin, or a B0NT / A8 toxin; or wherein the belt-buckle region comprises amino acids 445 to 470 and 528 to 542 of a BoNT / A3 toxin.
[0045] In some embodiments, the toxin is a botulinum toxin type B, wherein the belt-buckle region comprises amino acids 442 to 466 and 519 to 533 of a BoNT / B1 toxin, a BoNT / B2 toxin, a BoNT / B3 toxin, a BoNT / B4 toxin, a BoNT / B5 toxin, a B0NT / B6 toxin, a BoNT / B7 toxin, or B0NT / B8 toxin.
[0046] In some embodiments, the toxin is a botulinum toxin type C, wherein the belt-buckle region comprises amino acids 450 to 475 and 534 to 542.
[0047] In some embodiments, the toxin is a botulinum toxin type D, wherein the belt-buckle region comprises amino acids 445 to 470 and 530 to 538.
[0048] In some embodiments, the toxin is a botulinum toxin type F, wherein the belt-buckle region comprises amino acids 440 to 465 and 518 to 534.
[0049] In some embodiments, the toxin is a botulinum toxin type G, wherein the belt-buckle region comprises amino acids 445 to 470 and 524 to 538.
[0050] In some embodiments, the present invention features a modified botulinum toxin type A1 (BoNT / A1), the toxin comprising: one or more mutations to at least one region of SEQ ID NO 1, the at least one region comprising amino acids 449-474 or 532-546; wherein the one or more mutations confer a faster onset of action as compared to a wild type botulinum toxin, while maintaining comparable potency and duration of action as the wild type botulinum toxin.Reference No.: UC2024-9AO, UCI 25.03 PCTInventor’s last name: Jin et alDocument Date: May 7, 2026
[0051] In some embodiments, the toxin comprises mutations to the following amino acids: amino acid 460; amino acid 464; and / or amino acid 543.
[0052] In some embodiments, the toxin comprises the following mutations: a W460G mutation; a F464G mutation; and a Y543G mutation. In some embodiments, the toxin comprises the following mutations: a W460G mutation. In some embodiments, the toxin comprises the following mutations: a W460G mutation and a F464G mutation. In some embodiments, the toxin comprises the following mutations: a W460G mutation and a Y543G mutation. In some embodiments, the toxin comprises the following mutations: a F464G mutation. In some embodiments, the toxin comprises the following mutations: a F464G mutation and a Y543G mutation. In some embodiments, the toxin comprises the following mutations: a Y543G mutation. See, for example, FIG. 5A and FIG. 5B.
[0053] In some embodiments, mutations described herein involving replacement of a wild type amino acid with a glycine residue in the mutant (e g., W460G, wherein the amino acid tryptophan (W) at position 460 in the sequence is replaced by glycine (G)) may alternatively be replaced instead with alanine or serine, or any other amino acid with suitable physicochemical properties. For example, a W460G mutation may alternatively be a W460A mutation (wherein tryptophan is replaced with alanine), a W460S mutation (wherein tryptophan is replaced with serine), or any other mutation wherein tryptophan is replaced with an amino acid having suitable physiochemical properties, e.g., an amino acid having physiochemical properties similar to glycine.
[0054] In some embodiments, the present invention features a method of producing a modified botulinum toxin, comprising: modifying a conformation of a belt region of the modified botulinum toxin; wherein the belt region comprises at least a portion of an N-terminal region of a heavy chain of the modified botulinum toxin; wherein the belt region of the modified botulinum toxin has either a more constrained or less constrained belt region as compared to a wild type botulinum toxin; wherein the more constrained belt region as compared to a wild type botulinum toxin produces a modified botulinum toxin with at least one of slower onset of action and reduced potency as compared to the wild type botulinum toxin; wherein the less constrained belt region as compared to a wild type botulinum toxin produces a modified botulinum toxin with a faster onset of action as compared to the wild type botulinum toxin.
[0055] In some embodiments, modifying the conformation of the belt region of the modified botulinum toxin comprises binding an antibody to the modified botulinum toxin.
[0056] In some embodiments, modifying the conformation of the belt region of the modified botulinum toxin comprises mutating one or more amino acids in the belt-buckle region of the toxin.
[0057] In some embodiments, the belt region is more constrained as compared to a wild type botulinum toxin due to binding of an antibody to the modified botulinum toxin.
[0058] In some embodiments, the belt region is less constrained as compared to a wild type botulinum toxin due to binding of an antibody to the modified botulinum toxin.Reference No.: UC2024-9AO, UCI 25.03 PCTInventor’s last name: Jin et alDocument Date: May 7, 2026
[0059] In some embodiments, the belt region is more constrained as compared to a wild type botulinum toxin due to mutating one or more amino acids in the belt region of the modified botulinum toxin.
[0060] In some embodiments, the belt region is less constrained as compared to a wild type botulinum toxin due to mutating one or more amino acids in the belt-buckle region of the modified botulinum toxin
[0061] BoNTs are initially synthesized as single polypeptide chains, which are cleaved by proteases at a loop connecting the LC and HC to yield the mature toxins. The belt is the N-terminal segment of the HC right downstream of the cleavage site, consisting of two unique largely unstructured loops. For example, the first segment of the BoNT / E belt, consisting of residues K423-D456, extends in parallel to the long helices of the HNand interacts with both the LC and HN. The second segment of the belt, consisting of residues T457-N515, fully encircles the LC much like a strap and returns to the starting point of the belt. Notably, the C-terminal tip of the LC, forming a p sheet, is sandwiched between the N- and C-termini of the belt with each forming a p sheet, resembling a strap passing through a buckle
[0062] Structural comparison showed that the belt of BoNT / E does not bind to its LC-HNfragment as tight as that of BoNT / A and BoNT / B. For example, while the complete belts are well defined in the structures of BoNT / A and BoNT / B, residues P499-N515 and N461-E465 of BoNT / E belt are too flexible to be resolved in the cryo-EM and crystal structures, respectively, indicating weak or no interactions with LC / E in these areas Another unique feature of the BoNT / E belt is that a portion of it around residues D457-N476 is sandwiched between HCE and LC / E when BoNT / E adopts a closed-wing conformation, burying -404 A2 of solvent accessible interface. In the crystal structure of LC-HN / E when HCE is absent, almost the entire second segment of the BoNT / E belt (residues V458-K500), is too flexible to be resolved. In contrast, the belts of BoNT / A and BoNT / B do not interact with their Hcin the context of holotoxins, and they wrap around their respective LC tightly with fully visible electron densities in the crystal structures of LC-HN / A and LC-HN / B in the absence of their Hcdomains. These findings suggest that the belt of BoNT / E is intrinsically more flexible and associates more loosely with its LC-HNfragment than that of BoNT / A and BoNT / B, requiring additional support from HCE and resulting in the unique closed-wing conformation.
[0063] The unique closed-wing conformation of BoNT / E observed at neutral pH and the higher flexibility of its belt led to the investigation of how BoNT / E, especially its belt, responds to acidic pH, a signal that triggers LC unfolding and membrane translocation once inside neurons. To this end, the cryo-EM structure of BoNT / Ei (a genetically inactivated form) was determined at pH 5. The analysis of the cryo-EM data yielded a well-defined electron density map for the LC-HNfragment of BoNT / E at 2.99 A resolution, resembling its structure at neutral pH, while the densities of HCE were largely undefined, suggesting a flexible conformation.
[0064] With further processing and classification of the cryo-EM data, a series of EM maps were obtained showing several open conformations of BoNT / E, in which the LC-HNmoiety remains largely unchanged with HCE adopting various orientations. The structure of a major conformation of BoNT / E at 3 A resolution was determined using - 64.46% of the total particles with observable HCE Low-resolution maps for four minor classes of BoNT / E were also reconstructed using -23.68%, -6.51%, -2.50%, andReference No.: UC2024-9AO, UCI 25.03 PCTInventor’s last name: Jin et alDocument Date: May 7, 2026-2.85% of total particles with observable HCE, respectively. Interestingly, the closed-wing conformation of BoNT / E was not observed at pH 5; instead, it adopts an ensemble of open states including a BoNT / A-like open-wing conformation and a semi-closed conformation that resembles the conformations of BoNT / A and tetanus neurotoxin (TeNT) observed in cryo-EM structures. These findings suggest that BoNT / E opens up its Hcdomain responding to vesicle acidification, prior to LC unfolding and membrane translocation.
[0065] The structure of the LC-HNfragment of BoNT / E at pH 5 is highly similar to that at neutral pH. However, HCE exhibits a large structural flexibility at pH 5, moving away from the LC-HNfragment. Notably, such re-orientation of HCE would abolish its interactions with the belt and LC / E, a key feature of the closed-wing conformation of BoNT / E at neutral pH. Consistent with this finding, most of the second segment of BoNT / E belt (V458-P481 in the LC-HNfragment and T457-K487 in Class 1 holotoxin) is too flexible to be observed at pH 5, resembling the structure of the isolated LC-HN / E fragment but not the conformation of the holotoxin in the closed-wing state at neutral pH. These findings suggest that the flexibility of the BoNT / E belt significantly increases upon vesicle acidification when the Hcmoves away from LC-HN, which may release its constraints on the belt and facilitate LC unfolding and transit into the next functional state of intoxication.
[0066] Interestingly, the major conformation of BoNT / E at pH 5 (Class 1 ) resembles that of BoNT / E and BoNT / A when they are bound with another clostridial protein non-toxic non-hemagglutinin (NTNH) at acidic pH. NTNH is one of non-toxic neurotoxin-associated proteins (NAPs) that is encoded in the same gene cluster as the corresponding BoNT, which assembles with BoNT into a highly stable minimal progenitor toxin complex (M-PTC). The M-PTC provides both proteins with high stability against acidic pH and digestive proteases in the gastrointestinal (Gl) tract during oral intoxication. The M-PTC disassembles upon entering the general circulation and sensing the neutral environment, leading to the release of BoNT.
[0067] Experimental data suggested that BoNT / E adopts a spectrum of flexible conformations at acidic pH including an M-PTC form, which could readily assemble with NTNH / E. In the M-PTC, part of the BoNT / E belt is protected by the nHcdomain of NTNH / E, mimicking the support from HCE in its closed-wing conformation. Therefore, the increased vulnerability of BoNT / E in the open conformation to degradation in the acidic Gl tract — particularly its more flexible belt — is mitigated by NTNH / E in the M-PTC.
[0068] The belt plays important roles in both the unfolding of the LC and the reorganization of the HNto form a protein-conducting channel. Here, cryo-EM studies reveal that the belt of BoNT / E is more flexible than that of BoNT / A and BoNT / B, and its flexibility increases at acidic pH when BoNT / E transits into open conformations with HCE moving away from the LC-HNfragment. This unique feature of the BoNT / E belt may help reduce the energy requirement for acidic pH-induced LC unfolding and translocation across the HNchannel, ultimately leading to a fast onset of BoNT / E action. To validate this hypothesis, one could attempt to strengthen the interactions between BoNT / E belt and the rest of toxin through protein engineering, with the expectation of slowing down the action of BoNT / E. However, this approach isReference No.: UC2024-9AO, UCI 25.03 PCTInventor’s last name: Jin et alDocument Date: May 7, 2026technically challenging due to its susceptibility to potential artifacts arising from non-specific effects of mutagenesis. To address this challenge, “reverse engineering” approach was utilized by using the slower-acting BoNT / A as a model and investigating whether loosening its belt by structure-based mutagenesis could enhance its speed of action.
[0069] An extensive protein-protein interaction network was identified between the belt and LC / A that mutually stabilize each other. The employed strategy was to rationally mutate key amino acids within the belt that anchor it to LC / A, while avoiding alterations to other parts of the toxin. Given the extensive interactions between the belt and LC / A, in order to effectively loosen the belt, it is crucial to identify and mutate hotspot residues that are responsible for key interactions. Otherwise, the interaction might remain largely intact due to redundancy and distributed binding energy. Therefore, five variants of BoNT / A were designed, carrying targeted mutations across distinct regions of the belt, aiming to identify a hotspot that can most effectively disrupt the belt-LC / A association. One variant contains mutations in three amino acids (E491G / E492G / N493G, referred to as EEN), which are located at the start of the second segment of the belt. Three variants involve mutations in four amino acids that are located in the middle section of the belt: F508G / E511G / N514G / D523G (termed FEND); F508G / N514G (FN); and N514G / D523G (ND). Another variant carries mutations in three amino acids, W460G / F464G / Y543G (WFY), which are located in the belt-buckle where the N- and C-termini of the belt associate with the C-terminal tail of the LC. Disrupting the belt-LC / A association through such designs, if successful, is believed to increase the flexibility of the belt, thus reducing its constraint on LC / A, without affecting the enzymatic activity of LC / A or the overall structure integrity of the toxin.
[0070] The recombinant LC-HN / A (M1-N875) was used as a platform to characterize the mutations described above. The behavior of these LC-HN / A variants in response to acidification could closely resemble that of the full-length BoNT / A because HCA neither interacts with the belt nor undergoes pH-dependent conformational changes by itself. It was found that, except for the FEND mutant, all four other mutants of LC-HN / A were successfully expressed in E. coli and purified to homogeneity in a manner comparable to the wild-type LC-HN / A. They were eluted as WT-like single peaks on a size-exclusion chromatography (SEC), indicating they adopt a WT-like structure. This finding therefore demonstrates that mutations introduced in these four LC-HNvariants do not adversely affect proper protein folding In contrast, the FEND mutant exhibited low expression and poor purity, suggesting that these mutations severely compromised proper protein folding, and was therefore not pursued for further studies.
[0071] Two independent assays were exploited to examine how the various mutations introduced in the belt might affect the pH-dependent conformational changes of LC-HN / A. First, an environment-sensitive dye 8-anilinonaphthalene-1 -sulfonic acid (ANS) was used as an indicator to examine the extent of unfolding of LC-HN / A at various pH. ANS dye displays increased fluorescence intensity upon binding to hydrophobic regions of a protein, which become progressively more exposed during unfolding. ANS intensity of the WT LC-HN / A increased when the pH decreased from 8.4 to 4.4, indicating that it gradually unfolded during acidification. The behaviors of the FN, ND, and EEN mutants were similar to that of the WT protein, suggesting the mutations they carried did not have a measurable effect on protein unfolding.Reference No.: UC2024-9AO, UCI 25.03 PCTInventor’s last name: Jin et alDocument Date: May 7, 2026However, the behavior of the WFY mutant was drastically different from the WT, which was more sensitive to acidic pH, unfolding more rapidly and extensively than the WT protein under these conditions These findings suggest that the stabilizing effect of the belt on the LC and HNis not uniformly distributed across it, with the belt-buckle playing a pivotal role in this process To verify proper folding of the WFY mutant, we conducted thrombin cleavage on both the WT and the WFY mutant, each containing a thrombin cleavage site inserted between LC / A and HN / A. The cleaved LC / A and HN / A migrated separately under reducing conditions. In contrast, under non-reducing conditions, the two fragments of the WFY mutant migrated as a single species, demonstrating that the connecting disulfide bond formed correctly.
[0072] A fluorescence-based thermal shift assay was conducted to examine the pH-dependent unfolding of LC-HN / A This assay assesses the thermal stability of a protein, monitoring changes in dye fluorescence as the protein unfolds with increasing temperature. A change in the melting temperature (Tm) indicates alterations in protein stability. The Tmof the LC-HN / A variants was examined at pHs ranging from 8.4 to 4.4. Compared to the WT LC-HN / A, the FN, ND, and EEN mutants showed similar or slightly decreased Tmvalues at each tested pH, while the WFY mutant exhibited the largest change. Notably, the WFY mutant exhibited a drastic 11 °C drop of its Tmat pH 4.4 compared tothe WT protein, indicating that mutating these three residues in the belt-buckle significantly destabilized LC-HN / A at acidic pH. These results are consistent with the ANS studies, collectively highlighting the belt-bucket as a critical regulatory checkpoint for stabilizing the LC and HN, while loosening the belt facilitates the acidic pH-triggered conformational change of LC-HN / A.
[0073] A secondary optimization study was performed focusing on the WFY mutant, where the single mutations such as W, F, or Y, and double mutations such as WF, WY, or FY were examined using the ASN-binding assay and the fluorescence-based thermal shift assay These data demonstrate that mutating any of these residues in the belt-buckle significantly destabilized LC-HN / A at acidic pH.
[0074] While the present invention is not limited to these mutations, in summary, any combination(s) of one or more of the following three mutations (including, but not necessarily limited to, single mutations, double mutations, and / or triple mutations) located in the belt, W460G and / or F464G and / or Y543G, can enhance the belt’s structural flexibility. The LC-HNfragment of BoNT / A carrying these three mutations is more sensitive to acidic pH and unfolds faster and extensively than the WT protein. This should lead to an accelerated speed of onset in the context of BoNT / A holotoxin.
[0075] Without wishing to limit the present invention to any particular theory or mechanism, similar mutations introduced in the belt-buckle of BoNT / B could enhance the belt’s structural flexibility The LC-HNfragment of BoNT / B carrying these mutations will be more sensitive to acidic pH and unfold faster and extensively than the WT protein. This should lead to an accelerated speed of onset in the context of BoNT / B holotoxin. The candidates for such mutations in the belt-buckle of BoNT / B include one or more of these amino acids: V449, N451, D453, L454, F455, F456, I457, I530, but not limited to these residues.
[0076] We next examined whether weakening the belt-buckle with the WFY mutations might affect the structure and function of BoNT / A. To this end, we recombinantly produced the inactivated BoNT / Ai-WFYReference No.: UC2024-9AO, UCI 25.03 PCTInventor’s last name: Jin et alDocument Date: May 7, 2026for structural characterization. To assess whether weakening the belt affects the overall architecture of BoNT / A, we performed negative-stain EM on BoNT / Ai-WT and BoNT / Ai-WFY, followed by 2D classification. Representative class averages from both samples showed similar particle shapes and domain organization, closely resembling the canonical architecture of wild-type BoNT / A (PDB: 3BTA). In these averages, the LC, HNand Hcdomains could be readily recognized based on the reference structure No obvious large-scale conformational differences were observed between BoNT / Ai-WT and BoNT / Ai-WFY at the negative-stain level, suggesting that the WFY mutations do not substantially perturb the overall architecture of the toxin. A low-resolution cryo-EM density map was obtained, indicating increased structural flexibility, likely arising from loosening of the belt region.
[0077] Monoclonal antibody (mAb)-based antitoxins against major BoNT serotypes have been developed. Interestingly, one potent human neutralizing antibody against BoNT / A (2G11), recognizes an epitope requiring both LC and HN. Prior efforts to map the 2G11 epitope using random mutant libraries were unsuccessful, suggesting that it may bind a 3D composite epitope involving both LC and HN. This led to the hypothesis that 2G11 may neutralize BoNT / A by interfering with unfolding and transportation of the LC, which could potentially involve the belt. Consequently, it was examined whether the belt loosening mutants described above could impact 2G11 binding. Remarkably, using a pull-down assay, it was found that 2G11 did not recognize the WFY mutant, either within the LC-HNfragment or the holotoxin, whereas it bound other LC-HNmutants with WT-like affinity. This finding suggests that the belt-buckle is likely part of the neutralizing epitope for 2G11.
[0078] To delve deeper into the neutralizing mechanism and functional relevance of the belt-buckle, the cryo-EM structure of BoNT / Ai in complex with the Fab fragment of 2G11 was determined. Analysis of the cryo-EM data yielded a high-quality electron density map for the LC-HNfragment of BoNT / Ai and the variable light chain (VL) and heavy chain (VH) of 2G11 at 3.06 A resolution. The densities for the Hcdomain of BoNT / Ai and the constant light chain and heavy chain of 2G11 were not sufficient for model building due to high structural flexibility, but they are outside the well-defined toxin-antibody interface.
[0079] The cryo-EM structure clearly reveals that 2G11 binds at the junction of LC and HNaround the belt-buckle area Detailed structural analysis revealed that 2G11 binds to two distinct regions on BoNT / Ai. First, 2G11 binds to an extended C-terminal segment of the BoNT / A belt (N533-K546) and “locks” it into the buckle area, burying an interface of -569 A2. This interface involves an extensive network of hydrogen bonds, salt-bridges, and hydrophobic interactions, with 13 of the 15 residues in this segment of the belt directly interacting with the VHand VLof 2G11, securing the belt in place. Notably, Y543 in the belt directly interacts with K102, Y103, C104, and C109 on 2G11. Mutating Y543, as seen in the WFY mutant, can significantly impair 2G11 binding to BoNT / A. Complementing its interaction with the belt, 2G11 binds a small loop T247-Y250 within the LC through two hydrogen bonds and several hydrophobic interactions. Furthermore, residue R432 in the buckle of BoNT / A is engaged in hydrogen bonds and hydrophobic interactions with residues S30, N31, V53 and G54 on the VHof 2G11. Together, these 2G11 -mediated interactions firmly stabilize the belt-buckle of BoNT / A, increasing the energy requirement for conformational changes in this area.Reference No.: UC2024-9AO, UCI 25.03 PCTInventor’s last name: Jin et alDocument Date: May 7, 2026
[0080] The overall structure of the 2G11-bound LC-HN / A closely resembles its free form, as observed in BoNT / A holotoxin (PDB: 3BTA) or the isolated LC-HN / A (PDB: 2W2D), with root mean square deviations (RMSDs) of -0.704 A and -1.079 A, respectively. Interestingly, the loop T247-Y250 in LC / A, which is recognized by 2G11, is either too flexible to be observed (PDB: 2IMC) or exhibiting a difference orientation (PDB: 1E1H and 1XTF) in several structures of the isolated LC / A Notably, this loop in LC / A is sandwiched between the N-terminal and C-terminal regions of the belt — where residues W460 / F464 and Y543 are located, respectively — in the context of LC-HN / A or the holotoxin. Such interactions mutually stabilize the belt and this loop, which may explain the increased flexibility of this loop in the isolated LC when the belt is absent. Conversely, when stabilized by 2G11, this loop can relay structural support to stabilize the belt. These structural findings suggest that 2G11 effectively stabilizes the belt-buckle area in BoNT / A. Interestingly, substitution of A50 with D50 during the affinity maturation of 2G11, derived from its parental antibody ING1, significantly contributes to its enhanced affinity This is primarily due to D50 on the VLof 2G11 forming a hydrogen bond with N248 of BoNT / A, along with a salt bridge with R100 on the VHof 2G11, which stabilizes the VL-VHinteractions.
[0081] Taken together, these structural findings demonstrate that 2G11 effectively stabilizes the structural integrity of the LC and belt-buckle in BoNT / A, preventing conformational changes in this area that are prerequisites for LC unfolding and translocation. In contrast, the engineered WFY mutations loosen the belt-buckle, not only disrupting 2G11 binding but also facilitating pH-dependent conformational changes in this area.
[0082] Remarkably, it was discovered that the binding mode of 2G11 to BoNT / A closely resembles that of a neutralizing VHH, JLE-E9, in its interaction with BoNT / E, after analyzing a large number of crystal structures of various BoNTs in complex with diverse single-domain camelid antibodies (VHHs) that have been developed in the course of developing the present invention. In fact, JLE-E9 binds to the belt-buckle area on BoNT / E1, with its binding site on BoNT / E almost completely overlapping that of the VHof 2G11 on BoNT / A, suggesting that they share similar neutralizing mechanisms. Consistently, experimental data obtained in the development of the present invention demonstrates that JLE-E9 binding stabilizes the structure of LC-HN / E, thereby inhibiting its conformational changes induced by acidic pH. These two neutralizing antibodies were developed using completely different strategies, yet both ultimately target the homologous belt-buckle in these two distinct BoNT serotypes. These findings suggest that the belt-buckle is likely one of the most vulnerable parts of BoNTs, serving a conserved functional role.
[0083] Given the functional importance of the belt-buckle in BoNT / A, it was examined how weakening the belt-buckle with the WFY mutations might affect the action of BoNT / A. To this end, the recombinant BoNT / A holotoxin carrying the single mutation F (F464G), double mutations WF (W460G / F464G) or FY (F464G / Y543G), or triple mutations WFY (W460G / F464G / Y543G) were produced in E. coli, which could be purified to homogeneity in a manner similar to the WT toxin. The first investigation into these mutant holotoxins examined the activity of these BoNT / A variants at neuromuscular junctions using the mouse phrenic hemidiaphragm (MPN) assay. This ex vivo method examines the activity of BoNT by recording the contractions of the mouse hemidiaphragm mounted in an organ bath in the presence of BoNT. The timeReference No.: UC2024-9AO, UCI 25.03 PCTInventor’s last name: Jin et alDocument Date: May 7, 2026interval between the application of BoNT and the point when the muscle contraction amplitude is reduced by half of its original value (paralysis time or t1 / 2) serves as an indicator of toxin efficacy. It was found that these BoNT / A variants are highly potent, with the F variant (F464G) exhibiting an improved potency (-206%) and the WF, FY, and WFY exhibiting a slightly decreased activity (-87%, 29%, and 37%, respectively) compared to the WT toxin
[0084] In the MPN assay, the action of BoNT is detected by hemidiaphragm paralysis within 2-3 hours as physiological read out, which comprises indirect electrical stimulation causing neurotransmitter release followed by depolarization and contraction of muscle tissue. The essential indirect stimulation also causes accelerated uptake of BoNTs into the motor neurons. To carefully dissect the onset of action of BoNTs, the direct measurement of intracellular SNAP-25 cleavage as a readout of BoNT biological activity in non-stimulated conditions over a period of up to 24 h was performed in a cell-based neuron assay using the WFY variant as a representative.
[0085] Here, differentiated mouse P19 neurons (P19N) derived from embryonal carcinoma cells were treated with WT BoNT / A and BoNT / A-WFY mutant at physiologically relevant concentrations ranging from 0.3-300 pM. After 2 h of treatment, BoNTs were washed away and the P19N were collected and lysed at 4, 8, 12, and 24 h post-treatment and analyzed by Western blotto quantify SNAP-25 cleaved by BoNT / A. Intriguingly, it was found that 3 pM of BoNT / A-WFY exhibited an equal potency as 30 pM of WT BoNT / A based on substrate cleavage at 4, 8, 12 h and 24 h post-treatment. More specifically, it was found that BoNT / A-WFY displayed a faster onset of action (EC50-10 pM) compared to the WT BoNT / A (EC50-300 pM) at 4 h. Over time, the WT BoNT / A gradually narrowed the gap, with EC50values of -3 pM for WFY and -30 pM for the WT at 8 h, and -2 pM for WFY and -20 pM for the WT at 12 h. By 24 h, 1 pM BoNT / A-WFY and 5 pM WT BoNT / A each achieved -50% SNAP-25 cleavage. Since the WFY mutations on the belt of BoNT / A do not affect receptor binding and uptake, LC enzymatic activity, and most other features of BoNT / A, the faster SNAP-25 cleavage by BoNT / A WFY than BoNT / A WT at comparable concentrations observed here indicates a faster progress of LC unfolding, translocation, refolding and LC release.
[0086] Besides 2G11, two other antibodies CR2 and RAZ1 bind HCA. Therefore, they should recognize BoNT / A-WFY as effectively as the WT toxin A combination of the two neutralizing antibodies protected mice against BoNT / A intoxication with very high potency (up to 10,000 LD50). Therefore, BoNT / A-WFY should be safe, which can be neutralized by available antibodies.
[0087] In addition, neutralization of BoNT / A-WFY vs WT was checked using the FDA-approved heptavalent equine botulism antitoxin (BAT®) in a variation of the MPN assay for detecting BoNT-neutralizing antibodies (BNA), referred to as the MPN-BNA assay. Dosages of BoNT / A WT and WFY mutant displaying similar biological activity were pre-incubated with BAT and the BoNT-BAT mixtures were tested in the MPN-BNA assay. The paralytic halftime for BoNT / A WT was prolonged from 66 minutes without BAT to 163 minutes with BAT, corresponding to 98% neutralization of BoNT / A WT biological activity by BAT. Similarly, BoNT / A-WFY showed a comparable prolongation of paralytic halftimeReference No.: UC2024-9AO, UCI 25.03 PCTInventor’s last name: Jin et alDocument Date: May 7, 2026from 70 minutes without BAT to 167 minutes with BAT, resulting in 94% neutralization of its biological activity by the licensed botulism antitoxin. These results demonstrate that the WFY mutations confined to the belt of BoNT / A, which alter the epitope for 2G11, do not allow escape from neutralization by the licensed polyclonal antitoxin.
[0088] BoNT / E takes effect faster than BoNT / A and BoNT / B. Since both BoNT / A and BoNT / E exploit the same receptor, SV2, for cell binding and entry and cleave the same substrate SNAP-25 with similar activity, it was puzzling what determines the varying speeds of onset between them. It was found that the higher flexibility of the belt of BoNT / E contributes to the speedy translocation of its LC compared to BoNT / A and BoNT / B by lowering the energy requirement for acidic pH-induced LC unfolding and delivery across the HNchannel into the cytosol. Furthermore, a regulatory checkpoint was identified, the belt-buckle, which modulates the loosening of the belt constraint on the LC-HNfragment in response to vesicle acidification. Preventing conformational changes in the belt-buckle of BoNT / A by an antibody effectively neutralizes the toxin. In contrast, destabilizing the belt-buckle of BoNT / A by protein engineering enhances the pH sensitivity of LC-HN / A, leading to accelerated speed of onset.
[0089] The belt is known as a surrogate pseudo-substrate inhibitor of the LC protease. It was found that the belt of BoNT / E has a more flexible conformation than that of BoNT / A and BoNT / B. To accommodate the loose belt, BoNT / E evolves to adopt a unique closed-wing conformation at neutral pH so HCE can provide additional supports to stabilize the belt. Contrary to the prevailing views that the closed-wing conformation of BoNT / E is more efficient than the open form of BoNT / A and BoNT / B for LC translocation, cryo-EM studies reveal that BoNT / E actually opens up at acidic pH, taking a spectrum of open conformations. As a result, the BoNT / E belt turns looser when HCE moves away from its LC-HN. These findings suggest that releasing the constraint of the belt at acidic pH may prime the LC-HNfor subsequent unfolding and translocation, and the looser belt of BoNT / E may allow quicker translocation and earlier action of the LC in the cytosol, eventually leading to quicker onset of BoNT / E. Interestingly, when BoNT / E encounters an acidic environment in the Gl tract during oral intoxication, it is “locked” by NTNH / E in the M-PTC with part of its belt protected by the nHcdomain of NTNH / E. As a result, the M-PTC prevents premature action of the LC-HNbefore it enters neurons, while also protecting the toxin against the harsh Gl environment.
[0090] It was examined whether loosening the belt of BoNT / A by protein engineering may allow it to take effect faster. To this end, several variants of the LC-HN / A were designed that carry mutations at selected regions of the belt to loosen its interactions with LC / A, while avoiding changes to other parts of the toxin. Interestingly, many of these mutations did not show any major effects on the stability or pH sensitivity of LC-HN / A, except for mutations (various combinations of one or more of W460G / F464G / Y543G) located in the belt-buckle. Mutating these three key LC / A-interacting residues on the belt destabilizes the local structure in this area, as evidenced by the loss of antibody 2G11 binding, which specifically recognizes this area on BoNT / A. As the loosened belt reduces its constraint on the LC and HN, LC-HN / A-WFY was more sensitive to acidic pH, unfolding more rapidly and extensively than the WT protein. In some embodiments, in contrast to the belt loosening effect of the WFY mutant, it was found that two antibodiesReference No.: UC2024-9AO, UCI 25.03 PCTInventor’s last name: Jin et alDocument Date: May 7, 2026targeting BoNT / A and BoNT / E, respectively, neutralize the toxins by stabilizing the belt-buckle, further establishing the belt-buckle as a critical regulatory checkpoint.
[0091] BoNT / A holotoxin carrying various combinations of one or more of the WFY mutations exhibits a faster onset of action compared to the wild-type BoNT / A on neurons, as evidenced by its superior EC50for SNAP-25 cleavage at each time point examined. It thus further proves that the WFY mutations located on the belt-buckle do not affect receptor binding, LC activity and its half-life inside neurons, and most other intrinsic features of BoNT / A. Therefore, these BoNT / A variants hold potential as fast-acting and still long-lasting BoNT / A, meeting the same therapeutic and cosmetic needs as the conventional BoNT / A while offering the added advantage of rapidly achieving functional outcomes. Furthermore, due to their increased structural flexibility and subsequent decreased overall biochemical stability, these BoNT / A variants may exhibit a shorter effective window of action — coupled with a fast onset — in vivo after therapeutic injection compared to WT BoNT / A. Consequently, these BoNT / A variants will likely show reduced diffusion from the injection sites, lowering the risk of unintended effects on adjacent muscles or systemic exposure. A similar strategy could be applied to engineer other BoNT serotypes with fast onset, since the regulatory mechanism of the belt-buckle is likely conserved across BoNTs. These new generations of BoNTs will offer unique opportunities for treating neurologic conditions requiring prompt therapy, as well as for cosmetic customers seeking rapid results. Conversely, the belt-buckle is the Achilles’ heel of BoNTs, which could be explored for the development of countermeasures
[0092] Sequences of the homologous belt and belt-buckle regions in various BoNT serotypes and subtypes are provided below, with the belt-buckle area bolded and underlined. The range of amino acids that comprise the belt and belt-buckle are also provided below in TABLE 1.
[0093] TABLE 1.SEQUENCE INFORMATION of BoNTs SEQ ID SEQUENCENO.BoNT / A1 1 ALNDLCIKVNNWDLFFSPSEDNFTNDLNKGE Belt (449 - 546) EITSDTNIEAAEENISLDLIQQYYLTFNFDNEP Belt-buckle (449-474 and 532-546) EN I SI EN LSS D 11 GQ LELMPNIERFPNGKKYEL DBoNT / A2 2 ALNDLCIKVNNWDLFFSPSEDNFTNDLDKVE Belt (449 - 546) EITADTNIEAAEENISLDLIQQYYLTFDFDNEP Belt-buckle (449-474 and 532-546) E N I S I EN LSS D 11 GQ LE P MPNIERFPNGKKYEL DBoNT / A3 3 ALNYLCIKVNNWDLFFSPSEDNFTNDLDKVE Belt (445 - 542) EITADTNIEAAEENISSDLIQQYYLTFDFDNEP Belt-buckle (445-470 and 528-542) E N I S I EN LSS D 11 GQ LE P MPNIERFPNGKKYEL NBoNT / A4 4 ALNELCIKVNNWDLFFSPSEDNFTNDLDKVE Belt (449 - 546) EITSDTNIEAAEENISLDLIQQYYLNFNFDNEP Belt-buckle (449-474 and 532-546)Reference No.: UC2024-9AO, UCI 25.03 PCTInventor’s last name: Jin et alDocument Date: May 7, 2026ENTSIENLSSDIIGQLEPMPNIERFPNGKKYE LDBoNT / A5 5 ALNDLCIKVNNWDLFFSPSEDNFTNDLNKGE Belt (449 - 546) EITSDTNIEAAEENISLDLIQQYYLTFNFDNEP Belt-buckle (449-474 and 532-546) EN I SI EN LSS D 11 GQ LELMPNIERFPNGKKYEL DB0NT / A6 6 ALNDLCIKVNNWDLFFSPSEDNFTNDLNKGE Belt (449 - 546) EITSDTNIEAAEENISLDLIQQYYLTFNFDNEP Belt-buckle (449-474 and 532-546) EN I SI EN LSS D 11 GQ LELMPNIERFPNGKKYEL DBoNT / A7 7 ALNDLCIKVNNWDLFFSPSEDNFTNDLNKGE Belt (449 - 546) EITSDTNIEAAEENISSDLIQQYYLTFNFDNEP Belt-buckle (449-474 and 532-546) EN I SI EN LSS D 11 GQ LELMPNIERFPNGKKYEL DB0NT / A8 8 ALNDLCIKVNNWDLFFSPSEDNFTNDLDKVE Belt (449 - 546) EITSDTNIEAAEENISLDLIQQYYLTFDFDNEP Belt-buckle (449-474 and 532-546) E N I S I EN LSS D 11 GQ LE P MPNIERFPNGKKYEL DBoNT / B1 9 APGICIDVDNEDLFFIADKNSFSDDLSKN E R I Belt (442 -533) EYNTQSNYIENDFPINELILDTDLISKIELPSEN Belt-buckle (442-466 and 519-533) TESLTDFNVDVPVYEKQPAIKKIFTD BoNT / B2 10 APGICIDVDNEDLFFIADKNSFSDDLSKN E R I Belt (442 -533) EYDTQSNYIENRSSIDELILDTNLISKIELPSEN Belt-buckle (442-466 and 519-533) TESLTDFNVDVPVYEKQPAIKKIFTD BoNT / B3 11 APGICIDVDNEDLFFIADKNSFSDDLSKNERI Belt (442 -533) EYDTQSNYIENRSSIDELILDTNLISKIELPSEN Belt-buckle (442-466 and 519-533) TESLTDFNVDVPVYEKQPAIKKIFTD BoNT / B4 12 VPGICIDVDNENLFFIADKNSFSDDLSKNERV Belt (442 -533) EYNTQNNYIGNDFPINELILDTDLISKIELPSEN Belt-buckle (442-466 and 519-533) TESLTDFNVDVPVYEKQPAIKKVFTD BoNT / B5 13 APGICIDVDNEDLFFIADKNSFSDDLSKNERI Belt (442 -533) AYNTQNNYIDNDFSINELILDTDLISKIELPSEN Belt-buckle (442-466 and 519-533) TESLTDFNVYVPEYKKQPAIKKIFTD B0NT / B6 14 APGICIDVDNEDLFFIADKNSFSDDLSKNERI Belt (442 - 533) EYDTQSNYIENRSSIDELILDTNLISKIELPSEN Belt-buckle (442-466 and 519-533) TESLTDFNVDVPVYEKQPAIKKFFTD BoNT / B7 15 APGICIDVDNEDLFFIADKNSFSDDLSKNERI Belt (442 -533) EYNTKNIYIENYFSINELILDTDLISGIELPSENT Belt-buckle (442-466 and 519-533) ESLTDFNVDVPVYEKQPAIKKIFTD B0NT / B8 16 APGICIDVDNEDLFFIADKNSFSDDLSKNERI Belt (442 - 533) EYNTQSNYIENDFSINELILDTDLISKIELPSEN Belt-buckle (442-466 and 519-533) TESLTDFNVDVPVYEKQPAIKKIFTD BoNT / C 17 TLDCRELLVKNTDLPFIGDISDVKTDIFLRKDI Belt (450 - 542) NEETEVIYYPDNVSVDQVILSKNTSEHGQLDL Belt-buckle (450-475 and 534-542) LYPSIDSESEILPGENQVFYDNRTQNVDReference No.: UC2024-9AO, UCI 25.03 PCTInventor’s last name: Jin et alDocument Date: May 7, 2026BoNT / D 18 RDDSTCIKVKNNRLPYVADKDSISQEIFENKI I Belt (445 -538) TDETNVQNYSDKFSLDESILDGQVPINPEIVD Belt-buckle (445-470 and 530-538) PLLPNVNMEPLNLPGEEIVFYDDITKYVD BoNT / F 19 APPRLCIRVNNRELFFVASESSYNENDINTPK Belt (440 - 534) EIDDTTNLNNNYRNNLDEVILDYNSETIPQISN Belt-buckle (440-465 and 518-534) QTLNTLVQDDSYVPRYDSNGTSEIEEHNVV BoNT / G 20 GKSEQCIIVNNEDLFFIANKDSFSKDLAKAET I Belt (445 -538) AYNTQNNTIENNFSIDQLILDNDLSSGIDLPNE Belt-buckle (445-470 and 524-538) NTEPFTNFDDIDIPVYIKQSALKKIFVD BoNT / E1 21 KSICIEINNGELFFVASENSYNDDN I NTPKE I D Belt (423 -515) DTVTSNNNYENDLDQVILNFNSESAPGLSDE Belt-buckle (423-446 and 499-515) KLNLTIQNDAYIPKYDSNGTSDIEQHDVN
[0094] EXAMPLE
[0095] The following is a non-limiting example of the present invention. It is to be understood that said example is not intended to limit the present invention in any way. Equivalents or substitutes are within the scope of the present invention.
[0096] Cloning, expression, and purification of recombinant proteins. The genes encoding the BoNTZAI LC-HN(residues 1-875) was cloned into a modified pET28a vector that has a 6xHis / SUMO tag introduced to the N-terminus and a twin-strep II tag introduced to the C-terminus. BoNT / Ai carrying two catalytically inactivating mutations (R363A / Y366F) was cloned to a modified pET22b vector with an N-terminai twin-strep II tag and C-terminal 6xHis tag The gene encoding BoNT / Ei carrying three catalytically inactive mutations (H212A / E213A / H216A) were cloned into a pGEX vector with the N-terminal GST and followed by a 3C cleavage site. All the mutants were obtained by QuikChange PCR and verified by sequencing.
[0097] The recombinant proteins were overexpressed in E. coli strain BL21-star (Invitrogen) The transformed cells were cultured at 37°C in Luria Broth medium supplemented with corresponding antibiotics. Protein expression was induced by adding 1 mM isopropyl-[3-D-thiogalactopyranoside (IPTG) when cell density (OD600) reached ~0.8. The temperature was then reduced to 18 °C, and the protein expression continued at 18 °C for 18 hours. Cells were harvested by centrifugation and stored at -80°C for future use
[0098] The cell pellets were lysed by sonication. The LC-HNvariants of BoNT / A were purified by Ni-NTA affinity resins (Qiagen) in a buffer containing 50 mM Tris, pH 85, 400 mM NaCI, and 30 mM imidazole The bound proteins were eluted with a similar buffer containing 400 mM imidazole. The His / SUMO tag was cleaved by SUMO-protease. These proteins were further purified using Strep-Tactin (IBA) affinity resins. The bound proteins were eluted by 20 mM HEPES, 150 mM NaCI, 50 mM D-biotin, pH 8.5, and further purified by gel filtration in 20 mM Tris, 250 mM NaCI, pH 8.5. The peak was pooled and concentrated to -5 mg / ml and stored at -80 °C until future use The inactive full length BoNT / AI and WFY mutant were purified using a similar protocol.Reference No.: UC2024-9AO, UCI 25.03 PCTInventor’s last name: Jin et alDocument Date: May 7, 2026
[0099] The BoNT / Ei protein was purified as previously described. The purified BoNT / Ei was dialyzed against a buffer containing 50mM MES, pH 5 and 100 mM NaCI.
[0100] The wild-type and mutated recombinant full-length activated BoNT / A1 were produced under biosafety level 2 containment, using the E. coli BL21 DE3 strain. All mutations were generated by two-step PCR and verified by DNA sequencing. BoNT / A1 and mutants, carrying C-terminal 6><His-tag, were purified using a Co2+-Talon matrix (Takara Bio Europe S.A.S., France) and eluted with 50 mM Tris-HCI (pH 8.0), 150 mM NaCI, and 250 mM imidazole. For proteolytic activation and removal of the affinity tag, BoNT / A1 was incubated for 16 h at room temperature with 0.01 U bovine thrombin (Sigma-Aldrich Chemie GmbH, Germany) per g of BoNT. Subsequent gel filtration (Superdex-200 SEC; GE Healthcare, Germany) was performed in phosphate-buffered saline (pH 7.4). For storage, BoNT / A1 and mutants were shock-frozen in liquid nitrogen and stored at -80 °C. Protein concentration was determined by A280 spectrometry. Homogeneity of proteins was verified by subjecting 320 pg of BoNT / A WT and WFY to analytical SEC (Superdex 200 Increase 10 / 300 GL). Purity and degree of activation was checked by 10% SDS-PAGE analysis.
[0101] For negative-stain EM sample preparation, 3.5 pl of BoNT / Ai-WT and BoNT / Ai-WFY at a concentration of 25 pg / ml was applied to glow-discharged carbon-coated copper grids (CF200-CU, 200 mesh). After incubation for 1 min, excess sample was blotted away, and the grids were stained with 2% (w / v) uranyl acetate for 1 min. The grids were then air-dried before imaging.
[0102] Negative-stain EM data were collected on a JEOL JEM-21 OOF transmission electron microscope operated at 200 kV. Images were recorded at a nominal magnification of 50 kX, corresponding to a pixel size of 1.7 A, using a Gatan OneView detector. Approximately 200 micrographs were collected for each sample with a defocus range of -1.7 to -3.1 pm.
[0103] All acquired micrographs were processed using cryoSPARC v4.4.1. Contrast transfer function (CTF) parameters were estimated using patch-based CTF estimation. Particles were automatically picked using the Blob Picker and then extracted for subsequent 2D classification. Multiple rounds of 2D classification were performed to remove junk particles and generate representative class averages.
[0104] Cryo-EM sample preparation and data acquisition For cryo-EM sample preparation of BoNT / Ei, 4 pl of purified complexes were applied at concentrations of ~0.5 mg / ml to glow-discharged holey carbon grids (Quantifoil Grid R1.2 / 1.3 Cu 300 mesh). The grids were blotted for 1 second using an FEI Vitrobot plunger at 10 °C and 100% humidity, and then plunge-frozen in liquid ethane cooled by liquid nitrogen. The frozen grids were stored in liquid nitrogen before use.
[0105] High-resolution cryo-EM data were collected on a Titan Krios electron microscope operating at 300 kV and equipped with a post-GIF Gatan K3 Summit (BioQuantum) direct electron detector in the Pacific Northwest Center for Cryo-EM (PNCC). All the datasets were collected using similar parameters. The microscope was operated at a magnification of 29kX resulting in a pixel size of 0.788 A All imagesReference No.: UC2024-9AO, UCI 25.03 PCTInventor’s last name: Jin et alDocument Date: May 7, 2026were automatically recorded using SerialEM. Movies were obtained at an accumulated dose of 50e / A2with defocus ranging from -0.7 to -2.3 m, with 65 frames per movie stack.
[0106] Regarding the antibody 2G11, the Fab fragment of the 2G11 antibody was generated using immobilized papain (Thermo Scientific), following the manufacturer's protocol. To prepare the BoNT / Ai-Fab complex, purified BoNT / Ai was mixed with the Fab fragment at a molar ratio of 1:1.5 and incubated on ice for 2 hours. The resulting complex was subsequently purified using a Superdex 200 10 / 300 GL column in a buffer containing 20 mM HEPES (pH 75) and 150 mM NaCI. The purified complex was concentrated to ~3.5 mg / ml for cryo-EM analysis.
[0107] For cryo-EM data collection, 4 pl of purified BoNT / Ai-Fab complex was applied at concentrations of ~0.2 mg / ml to glow-discharged holey carbon grids (Quantifoil Grid R1.2 / 1.3 Cu 300 mesh). The grids were blotted for 2 seconds using a Thermal Fisher Vitrobot M at 10 °C and 100% humidity, and then plunge-frozen in liquid propane cooled by liquid nitrogen. The frozen grids were stored in liquid nitrogen before use. High-resolution cryo-EM data were collected on a Titan Krios electron microscope operating at 300 kV and equipped with a post-GIF Gatan K3 Summit (BioQuantum) direct electron detector in the Pacific Northwest Center for Cryo-EM (PNCC). All the datasets were collected using similar parameters. The microscope was operated at a magnification of 105 kX resulting in a pixel size of 0.8266 A. All images were automatically recorded using SerialEM. Videos were obtained at an accumulated dose of 50 e- / A2with defocus ranging from -0.8 to -2.2 pm, with 59 frames per movie stack.
[0108] For cryo-EM data collection, 4 pl of purified BoNT / Ai-WFY supplemented with 0.05% OG (n-Octyl-p-D-Glucoside, Anatrace) was applied at concentrations of -2.5 mg / ml to glow-discharged holey carbon grids (Quantifoil Grid R1.2 / 1.3 Cu 300 mesh). The grids were blotted for 3 seconds using a Thermo Fisher Vitrobot Mark IV at 10°C and 100% humidity, and then plunge-frozen in liquid ethane cooled by liquid nitrogen. The frozen grids were stored in liquid nitrogen before use. High-resolution cryo-EM data were collected on a Titan Krios electron microscope operating at 300 kV and equipped with Selectris X energy filter with Falcon 4i camera at the Electron Imaging Center for Nanosystems (EICN) at the University of California, Los Angeles’s California NanoSystems Institute (CNSI). The microscope was operated at a magnification of 130 kX resulting in a pixel size of 0.97 A. All images were automatically recorded using EPU. Movies were obtained at an accumulated dose of 50 e / A2with defocus ranging from -0.8 to -2.8 pm.
[0109] Data processing and structure determination. All acquired videos were processed using cryoSPARC v4.4.1. The videos were motion-corrected and dose-weighted using the patch-based motion correction module. The contrast transfer function (CTF) of the resulting images were then subject to patch-based estimation. Particles were auto-picked using blob picker and template picker.
[0110] For the BoNT / Ei dataset, the particles were processed with rounds of 2D classification, and the selected particles were used for ab initio reconstruction, followed by further heterogeneous refinement.Reference No.: UC2024-9AO, UCI 25.03 PCTInventor’s last name: Jin et alDocument Date: May 7, 2026
[0111] For the LC-HNclass, M-PTC form class, and the other open classes of BoNT / Ei, the selected particles were used for non-uniform refinement. For the open class, the selected particles were further under 3D classification, 2D classification and followed by further non-uniform refinement.
[0112] For BoNT / Ai-Fab complex dataset, after rounds of 2D classification, the selected particles were used for ab initio reconstruction, followed by further non-uniform refinement.
[0113] For the BoNT / Ai-WFY dataset, after rounds of 2D classification, the selected particles were used for ab initio reconstruction, followed by heterogeneous refinement and further homogeneous refinement
[0114] For all processed EM maps, the average resolution was given by the Fourier Shell Correlation criterion (FSC 0.143). CryoSPARC was used to determine local resolution and sharpen the maps.
[0115] For model building of the LC-HN / E structure and the holotoxin in the M-PTC form, the reported structures of LC-HN / E (PDB: 7K84) and the M-PTC / E (PDB: 9ARJ) were used to fit into the cryo-EM maps in UCSF Chimera X, respectively.
[0116] For model building of the BoNT / Ai-Fab, the reported structure of BoNT / A (PDB: 3BTA) and Alphafold3 predicted Fab structure were used to fit into the cryo-EM maps in ChimeraX.
[0117] The initial structural models were then subject to iterative refinement using Coot (vO.8.1) and real-space refinement using Phenix (v1.20.1). Figures were generated using PyMOL (http: / / wwwpymol org) and ChimeraX Analysis of interaction surface carried out using PISA
[0118] ANS (8-anilinonaphthalene-1 -sulfonic acid) binding assay. 1 M of LC-HN / A variants was incubated with 200 M of ANS for 15 min Buffer was formulated with 50 mM StockOption pH Buffer kit with pH ranging from 3.4 to 8.4 (Hampton research, HR2-241) supplemented with 250 mM NaCI. Fluorescence intensities were recorded at 25°C using a Molecular Devices SpectraMax M2e spectrophotometer with excitation at 366 nm and emission at 482 nm. The fluorescence intensity was normalized by dividing that of wild-type LC-HN / A in pH 8.4. Error bars indicate SD of three replicate measurements.
[0119] Protein melting assay. The thermal stability of LC-HN / A variants were measured using a fluorescence-based thermal shift assay on a StepOne real-time PCR machine (Life Technologies). Buffer was formulated with 50 mM StockOption pH Buffer kit with pH ranging from 34 to 84 (Hampton research, HR2-241) supplement with 250 mM NaCI Immediately before the experiment, proteins (-025 mg / ml) were mixed with the fluorescent dye SYPRO Orange (Sigma-Aldrich), and the mixtures were heated from 25°C to 95°C in a linear ramp rate of 1.5 °C / min. The midpoint of the protein-melting curve (Tm) was determined using the analysis software provided by the instrument manufacturer. Data obtained from three independent experiments were averaged to generate the graph.
[0120] Pull-down assay The interactions between antibody 2G11 and BoNT / Ai or LC-HN / A variants were investigated using a pull-down assay. Protein A resins (Genscript) were utilized in a PBS buffer (pH 7.4)Reference No.: UC2024-9AO, UCI 25.03 PCTInventor’s last name: Jin et alDocument Date: May 7, 2026containing 0.5% Tween-20 (PBS-TW20). Antibody 2G11 was employed as bait, while BoNT / Ai or LC-HN / A variants served as prey. Antibody 2G11 was first incubated with protein A resins at room temperature for 1 hour to allow binding. Following incubation, unbound 2G11 were removed by washing the resins twice with the PBS-TW20 buffer. The resins were then aliquoted and mixed with LC-HN / A or BoNT / Ai variants at approximately 3-fold molar excess over 2G11 The reaction mixtures were incubated at room temperature for 2 hours, followed by two washes in the PBS-TW20 buffer. The bound proteins were eluted by boiling the resins in SDS-PAGE loading buffer at 95°C for 5 minutes, followed by SDS-PAGE analysis and subsequent staining with BlinkBlue (Biotimes)
[0121] The MPN assay was performed employing 20-30 g Swiss mice (Janvier SA, France) as described previously. Mice were euthanized by CO2anesthesia and subsequently exsanguinated. The phrenic nerve hemidiaphragm tissue was explanted, placed into an organ bath and continuously stimulated at 5-25 mA with a frequency of 1 Hz and a 0.1 ms pulse duration. Isometric contractions were transformed using a force transducer and recorded with VitroDat Online software (FMI GmbH, Germany). The time required to decrease the amplitude to 50% of the starting value (paralytic half-time) was determined. To allow comparison of the altered neurotoxicity of mutants with BoNT / A1 WT (displaying a specific biological activity of 687 x 107± 1.15 x 107mouse LD50 / mg, mean ± SD), its MPN assay dose-response-curve logarithmic function (y(BoNT / A wild-type; 095, 1 9, 3.8 pM) = -21.64 ln(x) + 90.194, R2= 0.998) consisting of three concentrations determined in minimum 5 replicates was established. Accordingly, a dose-response-curve logarithmic function for the mutant (y(BoNT / A WFY; 25, 5.0, 10 pM) = -35 11 ln(x) + 135.17, R2= 0.965) consisting of three concentrations determined in 3-5 replicates each was determined. Employing the inverse logarithmic functions of the dose-response curves, the theoretical concentrations of BoNT / A WT and WFY mutant causing a paralytic half-time of 75 minutes were calculated (2.05 pM vs 5.56 pM) and the BoNT / A WFY biological activity was expressed as relative biological activity of BoNT / A WT.
[0122] Neutralization of BoNT by MPN-BNA assay. To test the neutralization of BoNTs by the heptavalent equine botulism antitoxin licensed in US (BAT®) dosages of BoNT / A WT (3.3 pM) and BoNT / A WFY (7.5 pM) causing similar paralytic half-times were preincubated with 3.5 mU / mL of BAT® or without antitoxin for 60 minutes at 37°C and subsequently checked for resulting paralytic halftimes in a variation of the above described MPN assay to detect BoNT-neutralizing antibodies (BNA) Resulting paralytic halftimes can be calculated into theoretical BoNT concentrations using the respective inverse functions of the dose-response-curves and expressed as relative neutralization due to AT treatment.
[0123] P19N substrate cleavage assay. P19 embryonal carcinoma cells were differentiated to neurons by retinoic acid (RA) treatment as previously described with minor changes. Briefly, P19 cells were maintained in an undifferentiated state with a confluence of max. 90% at 37°C with 5% CO2in MEM (Thermo Fisher) supplemented with 10% FCS and a combination of penicillin (50 U / mL) and streptomycin (50 pg / mL) (MEM++). For differentiation, 1.0 x 106cells in 15 ml MEM++ were seeded on petri dishes (Sarstedt) in the presence of 5 x 10-7M RA (Sigma Aldrich). After four days of incubation at 37°C with 5% CO2, growing cell aggregates, so called embryoid bodies, were washed with 10 mL PBS, trypsinized andReference No.: UC2024-9AO, UCI 25.03 PCTInventor’s last name: Jin et alDocument Date: May 7, 2026plated onto poly-D-lysine coated 24-well plates (3 g / cm2PDL, Thermo Fisher) at a density of 20 x 105cells / well. The medium was exchanged to Neurobasal medium (Thermo Fisher) supplemented with B-27 (Thermo Fisher) and penicillin / streptomycin (described above) (Neurobasal medium++) after 4 hours when the cells show adherence. Every two days, medium was replaced with fresh Neurobasal medium++. For neuron-specific selection of differentiated P19 neurons (P19N), (8 x 10'6M) cytosine arabinoside (AraC, Sigma Aldrich) was added to the medium four days after seeding and experiments were conducted within eight to twelve days after seeding.
[0124] For BoNT cell based assay, the P19N were incubated with concentration series of BoNT / A WT and BoNT / A WFY ranging from 0.3-300 pM in 500 L Neurobasal medium++ at 37°C and 5% CO2for 2 h. Cells w / o BoNT served as negative controls. After two hours, non-bound / -endocytosed BoNT was removed and P19N were washed with 500 pL PBS and subsequently incubated in 500 pL untreated Neurobasal medium++ for additional 2 h, 6 h, 10 h and 22 h. Incubation was terminated by a wash step with 500 pL PBS and P19N were incubated in 50 pL lysis buffer (200 mM NaCI, 1% NP40, 1 mM DTT, 1 mM EDTA, pH 8) for 30 minutes at 4°C P19N lysates were separated from cellular debris by centrifugation at 20.000 xg for 10 minutes at 4°C and subjected to western blot analysis. Cleaved SNAP-25 was detected by the mouse monoclonal anti-SNAP-25 antibody clone 71.2 (#111111; Synaptic Systems GmbH, Gottingen, Germany) while VAMP-2 serving as control protein was detected by the mouse monoclonal anti-VAMP-2 antibody clone 69.1 (#104211; Synaptic Systems GmbH, Gottingen, Germany). ECL signals were quantified by Imaged software package and analyzed by GraphPad Prism 10 software.
[0125] EMBODIMENTS
[0126] The following are non-limiting embodiments of the present invention. It is to be understood that said embodiments are not intended to limit the present invention in any way. Equivalents or substitutes are within the scope of the present invention.
[0127] Embodiment 1: A modified botulinum toxin, the toxin comprising: one or more mutations to a belt-buckle region of the toxin; wherein the one or more mutations confer a faster onset of action as compared to a wild type botulinum toxin, while maintaining comparable potency and duration of action as the wild type botulinum toxin.
[0128] Embodiment 2: The modified botulinum toxin of embodiment 1, wherein the toxin is a botulinum toxin selected from one of botulinum toxin type A, botulinum toxin type B, botulinum toxin type C, botulinum toxin type D, botulinum toxin type F, or botulinum toxin type G.
[0129] Embodiment 3: The modified botulinum toxin of any one of embodiments 1-2, wherein the toxin is a botulinum toxin type A selected from botulinum toxin subtype A1, botulinum toxin subtype A2, botulinum toxin subtype A3, botulinum toxin subtype A4, botulinum toxin subtype A5, botulinum toxin subtype A6, botulinum toxin subtype A7, or botulinum toxin subtype A8.
[0130] Embodiment 4: The modified botulinum toxin of any one of embodiments 1-2, wherein the toxin isReference No.: UC2024-9AO, UCI 25.03 PCTInventor’s last name: Jin et alDocument Date: May 7, 2026a botulinum toxin type B selected from botulinum toxin subtype B1, botulinum toxin subtype B2, botulinum toxin subtype B3, botulinum toxin subtype B4, botulinum toxin subtype B5, botulinum toxin subtype B6, botulinum toxin subtype B7, or botulinum toxin subtype B8.
[0131] Embodiment 5: The modified botulinum toxin of any one of embodiments 1-3, wherein the toxin is a botulinum toxin type A, wherein a belt-buckle region comprises amino acids 449 to 474 and 532 to 546 of a BoNT / A1 toxin, BoNT / A2 toxin; a BoNT / A4 toxin, a BoNT / A5 toxin, a B0NT / A6 toxin, a BoNT / A7 toxin, or a B0NT / A8 toxin; or wherein the belt-buckle region comprises amino acids 445 to 470 and 528 to 542 of a BoNT / A3 toxin.
[0132] Embodiment 6: The modified botulinum toxin of any one of embodiments 1-2 or 4, wherein the toxin is a botulinum toxin type B, wherein the belt-buckle region comprises amino acids 442 to 466 and 519 to 533 of a BoNT / B1 toxin, a BoNT / B2 toxin, a BoNT / B3 toxin, a BoNT / B4 toxin, a BoNT / B5 toxin, a B0NT / B6 toxin, a BoNT / B7 toxin, or B0NT / B8 toxin.
[0133] Embodiment 7: The modified botulinum toxin of any one of embodiments 1-2, wherein the toxin is a botulinum toxin type C, wherein the belt-buckle region comprises amino acids 450 to 475 and 534 to 542.
[0134] Embodiment 8: The modified botulinum toxin of any one of embodiments 1-2, wherein the toxin is a botulinum toxin type D, wherein the belt-buckle region comprises amino acids 445 to 470 and 530 to 538.
[0135] Embodiment 9: The modified botulinum toxin of any one of embodiments 1-2, wherein the toxin is a botulinum toxin type F, wherein the belt-buckle region comprises amino acids 440 to 465 and 518 to 534.
[0136] Embodiment 10: The modified botulinum toxin of any one of embodiment 1-2, wherein the toxin is a botulinum toxin type G, wherein the belt-buckle region comprises amino acids 445 to 470 and 524 to 538.
[0137] Embodiment 11: A modified botulinum toxin type A1 (BoNT / A1), the toxin comprising: one or more mutations to at least one region of SEQ ID NO. 1, the at least one region comprising amino acids 449-474 or 532-546; wherein the one or more mutations confer a faster onset of action as compared to a wild type botulinum toxin, while maintaining comparable potency and duration of action as the wild type botulinum toxin.
[0138] Embodiment 12: The modified botulinum toxin of embodiment 11, wherein the toxin comprises mutations to one or more of the following amino acids: amino acid 460; amino acid 464; or amino acid 543.
[0139] Embodiment 13: The modified botulinum toxin of any one of embodiments 11-12, wherein the toxin comprises one or more of the following mutations: a W460G mutation; a F464G mutation; or aReference No.: UC2024-9AO, UCI 25.03 PCTInventor’s last name: Jin et alDocument Date: May 7, 2026Y543G mutation.
[0140] Embodiment 14: A method of producing a modified botulinum toxin, comprising: modifying a conformation of a belt region of the modified botulinum toxin; wherein the belt region comprises at least a portion of an N-terminal region of a heavy chain of the modified botulinum toxin; wherein the belt region of the modified botulinum toxin has either a more constrained or less constrained belt region as compared to a wild type botulinum toxin; wherein the more constrained belt region as compared to a wild type botulinum toxin produces a modified botulinum toxin with at least one of slower onset of action and reduced potency as compared to the wild type botulinum toxin; and wherein the less constrained belt region as compared to a wild type botulinum toxin produces a modified botulinum toxin with a faster onset of action as compared to the wild type botulinum toxin.
[0141] Embodiment 15: The method of embodiment 14, wherein modifying the conformation of the belt region of the modified botulinum toxin comprises binding an antibody to the modified botulinum toxin.
[0142] Embodiment 16: The method of any one of embodiments 14-15, wherein modifying the conformation of the belt region of the modified botulinum toxin comprises mutating one or more amino acids in a belt-buckle region of the toxin.
[0143] Embodiment 17: The method of any one of embodiments 14-16, wherein the belt region is more constrained as compared to a wild type botulinum toxin due to binding of an antibody to the modified botulinum toxin.
[0144] Embodiment 18: The method of any one of embodiments 14-17, wherein the belt region is less constrained as compared to a wild type botulinum toxin due to binding of an antibody to the modified botulinum toxin.
[0145] Embodiment 19: The method of any one of embodiments 14-18, wherein the belt region is more constrained as compared to a wild type botulinum toxin due to mutating one or more amino acids in the belt region of the modified botulinum toxin.
[0146] Embodiment 20: The method of any one of embodiments 14-19, wherein the belt region is less constrained as compared to a wild type botulinum toxin due to mutating one or more amino acids in a belt-buckle region of the modified botulinum toxin.
[0147] As used herein, the term “about” refers to plus or minus 10% of the referenced number
[0148] Although there has been shown and described the preferred embodiment of the present invention, it will be readily apparent to those skilled in the art that modifications may be made thereto which do not exceed the scope of the appended claims. Therefore, the scope of the invention is only to be limited by the following claims. In some embodiments, the figures presented in this patent application are drawn to scale, including the angles, ratios of dimensions, etc. In some embodiments, the figures are representative only and the claims are not limited by the dimensions of the figures. In some embodiments,Reference No.: UC2024-9AO, UCI 25.03 PCTInventor’s last name: Jin et alDocument Date: May 7, 2026descriptions of the inventions described herein using the phrase “comprising” includes embodiments that could be described as “consisting essentially of” or “consisting of”, and as such the written description requirement for claiming one or more embodiments of the present invention using the phrase “consisting essentially of” or “consisting of” is met.
[0149] Reference numbers recited herein, in the drawings, and in the claims are solely for ease of examination of this patent application and are exemplary. The reference numbers are not intended in any way to limit the scope of the claims to the particular features having the corresponding reference numbers in the drawings.
Claims
Reference No.: UC2024-9AO, UCI 25.03 PCTInventor’s last name: Jin et alDocument Date: May 7, 2026WHAT IS CLAIMED IS:1) A modified botulinum toxin, the toxin comprising: one or more mutations to a belt-buckle region of the toxin;wherein the one or more mutations confer a faster onset of action as compared to a wild type botulinum toxin, while maintaining comparable potency and duration of action as the wild type botulinum toxin.2) The modified botulinum toxin of claim 1, wherein the toxin is a botulinum toxin selected from one of botulinum toxin type A, botulinum toxin type B, botulinum toxin type C, botulinum toxin type D, botulinum toxin type F, or botulinum toxin type G.3) The modified botulinum toxin of claim 2, wherein the toxin is a botulinum toxin type A selected from botulinum toxin subtype A1, botulinum toxin subtype A2, botulinum toxin subtype A3, botulinum toxin subtype A4, botulinum toxin subtype A5, botulinum toxin subtype A6, botulinum toxin subtype A7, or botulinum toxin subtype A84) The modified botulinum toxin of claim 2, wherein the toxin is a botulinum toxin type B selected from botulinum toxin subtype B1, botulinum toxin subtype B2, botulinum toxin subtype B3, botulinum toxin subtype B4, botulinum toxin subtype B5, botulinum toxin subtype B6, botulinum toxin subtype B7, or botulinum toxin subtype B8.5) The modified botulinum toxin of claim 2, wherein the toxin is a botulinum toxin type A, wherein a belt-buckle region comprises amino acids 449 to 474 and 532 to 546 of a BoNTZAI toxin, BoNT / A2 toxin; a BoNT / A4 toxin, a BoNT / A5 toxin, a B0NT / A6 toxin, a BoNT / A7 toxin, or a B0NT / A8 toxin; orwherein the belt-buckle region comprises amino acids 445 to 470 and 528 to 542 of a BoNT / A3 toxin.6) The modified botulinum toxin of claim 2, wherein the toxin is a botulinum toxin type B, wherein the belt-buckle region comprises amino acids 442 to 466 and 519 to 533 of a BoNT / B1 toxin, a BoNT / B2 toxin, a BoNT / B3 toxin, a BoNT / B4 toxin, a BoNT / B5 toxin, a B0NT / B6 toxin, a BoNT / B7 toxin, or B0NT / B8 toxin.7) The modified botulinum toxin of claim 2, wherein the toxin is a botulinum toxin type C, wherein the belt-buckle region comprises amino acids 450 to 475 and 534 to 542.8) The modified botulinum toxin of claim 2, wherein the toxin is a botulinum toxin type D, wherein the belt-buckle region comprises amino acids 445 to 470 and 530 to 538.9) The modified botulinum toxin of claim 2, wherein the toxin is a botulinum toxin type F, wherein theReference No.: UC2024-9AO, UCI 25.03 PCTInventor’s last name: Jin et alDocument Date: May 7, 2026belt-buckle region comprises amino acids 440 to 465 and 518 to 534.10) The modified botulinum toxin of claim 2, wherein the toxin is a botulinum toxin type G, wherein the belt-buckle region comprises amino acids 445 to 470 and 524 to 538.11) A modified botulinum toxin type A1 (BoNT / A1), the toxin comprising: one or more mutations to at least one region of SEQ ID NO. 1, the at least one region comprising amino acids 449-474 or 532-546;wherein the one or more mutations confer a faster onset of action as compared to a wild type botulinum toxin, while maintaining comparable potency and duration of action as the wild type botulinum toxin.12) The modified botulinum toxin of claim 11, wherein the toxin comprises mutations to one or more of the following amino acids:a) amino acid 460;b) amino acid 464; orc) amino acid 543.13) The modified botulinum toxin of claim 11, wherein the toxin comprises one or more of the following mutations:a) a W460G mutation;b) a F464G mutation; orc) a Y543G mutation.14) A method of producing a modified botulinum toxin, comprising: modifying a conformation of a belt region of the modified botulinum toxin;wherein the belt region comprises at least a portion of an N-terminal region of a heavy chain of the modified botulinum toxin;wherein the belt region of the modified botulinum toxin has either a more constrained or less constrained belt region as compared to a wild type botulinum toxin;wherein the more constrained belt region as compared to a wild type botulinum toxin produces a modified botulinum toxin with at least one of slower onset of action and reduced potency as compared to the wild type botulinum toxin; andwherein the less constrained belt region as compared to a wild type botulinum toxin produces aReference No.: UC2024-9AO, UCI 25.03 PCTInventor’s last name: Jin et alDocument Date: May 7, 2026modified botulinum toxin with a faster onset of action as compared to the wild type botulinum toxin.15) The method of claim 14, wherein modifying the conformation of the belt region of the modified botulinum toxin comprises binding an antibody to the modified botulinum toxin.16) The method of claim 14, wherein modifying the conformation of the belt region of the modified botulinum toxin comprises mutating one or more amino acids in a belt-buckle region of the toxin.17) The method of claim 14, wherein the belt region is more constrained as compared to a wild type botulinum toxin due to binding of an antibody to the modified botulinum toxin.18) The method of claim 14, wherein the belt region is less constrained as compared to a wild type botulinum toxin due to binding of an antibody to the modified botulinum toxin.19) The method of claim 14, wherein the belt region is more constrained as compared to a wild type botulinum toxin due to mutating one or more amino acids in the belt region of the modified botulinum toxin.20) The method of claim 14, wherein the belt region is less constrained as compared to a wild type botulinum toxin due to mutating one or more amino acids in a belt-buckle region of the modified botulinum toxin.
